PD-1 independent of PD-L1 ligation promotes glioblastoma growth through the NFκB pathway

Reza Mirzaei, Ashley M. Gordon, Franz J. Zemp, Mehul Kumar, Susobhan Sarkar, H. Artee Luchman, Anita C. Bellail, Chunhai Hao, Douglas J. Mahoney, Jeff F. Dunn,

Science Advances · 2021 · 37 citations · 48 references

DOIFull text

Open access

Concepts

Abstract

Brain tumor–initiating cells (BTICs) drive glioblastoma growth through not fully understood mechanisms. Here, we found that about 8% of cells within the human glioblastoma microenvironment coexpress programmed cell death 1 (PD-1) and BTIC marker. Gain- or loss-of-function studies revealed that tumor-intrinsic PD-1 promoted proliferation and self-renewal of BTICs. Phosphorylation of tyrosines within the cytoplasmic tail of PD-1 recruited Src homology 2–containing phosphatase 2 and activated the nuclear factor kB in BTICs. Notably, the tumor-intrinsic promoting effects of PD-1 did not require programmed cell death ligand 1(PD-L1) ligation; thus, the therapeutic antibodies inhibiting PD-1/PD-L1 interaction could not overcome the growth advantage of PD-1 in BTICs. Last, BTIC-intrinsic PD-1 accelerated intracranial tumor growth, and this occurred in mice lacking T and B cells. These findings point to a critical role for PD-1 in BTICs and uncover a nonimmune resistance mechanism of patients with glioblastoma to PD-1– or PD-L1–blocking therapies.

References

48